You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 醫藥股普跌,醫保局將常態化開展藥品和高值醫用耗材集採
格隆匯2月11日丨港股醫藥股普遍下跌,信達生物跌7.3%、中國先鋒醫藥跌近6%,凱萊英、石藥集團跌5%,石四藥集團、東陽光藥、復星醫藥跌逾3%。國新辦今日召開政策例行吹風會,國家醫保局副局長陳金甫介紹,下一步,國家醫保局將常態化制度化開展藥品和高值醫用耗材集中帶量採購,使集採成為公立醫療機構採購的基本模式。藥品集採在化學藥、中成藥、生物藥三大板塊全方位開展,高值醫用耗材重點聚焦骨科耗材、藥物球囊、種植牙等品種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account